Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Not yet recruiting1
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

not_yet_recruiting133%
completed133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingphase_2

Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy

NCT06914050
recruiting

A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer

NCT06323265
completedphase_2

Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer

NCT00001499

Clinical Trials (3)

Showing 3 of 3 trials
NCT06914050Phase 2

Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy

Not Yet Recruiting
NCT06323265

A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Recruiting
NCT00001499Phase 2

Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3